Baying for a flexible drug price.
出版信息
Lancet. 2009 Nov 28;374(9704):1794. doi: 10.1016/S0140-6736(09)62045-6.
Abstract
摘要
相似文献
1
Baying for a flexible drug price.
Lancet. 2009 Nov 28;374(9704):1794. doi: 10.1016/S0140-6736(09)62045-6.
2
Health-related quality of life and sorafenib.健康相关生活质量与索拉非尼
Hepatology. 2010 Oct;52(4):1523. doi: 10.1002/hep.23756.
3
From a cancer drug fund to value based pricing of drugs.从癌症药物基金到基于价值的药品定价。
BMJ. 2010 Aug 12;341:c4388. doi: 10.1136/bmj.c4388.
4
Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.索拉非尼治疗不可切除肝细胞癌的经济学评价。
J Gastroenterol Hepatol. 2010 Nov;25(11):1739-46. doi: 10.1111/j.1440-1746.2010.06404.x.
5
NICE rules that drug used in advanced liver cancer is not cost effective for the NHS.英国国家卫生与临床优化研究所（NICE）规定，用于晚期肝癌的药物对英国国民医疗服务体系（NHS）而言不具有成本效益。
BMJ. 2009 Nov 23;339:b4956. doi: 10.1136/bmj.b4956.
6
Sorafenib in hepatocellular carcinoma.索拉非尼用于肝细胞癌的治疗。
Br J Hosp Med (Lond). 2010 Aug;71(8):451-6. doi: 10.12968/hmed.2010.71.8.77669.
7
Impact of restricting access to high-cost medications for hepatocellular carcinoma.限制肝癌高费用药物的可及性的影响。
Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):465-73. doi: 10.1586/erp.12.33.
8
Hepatocellular carcinoma: sorafenib before liver transplantation?肝细胞癌：肝移植前使用索拉非尼？
Hepatology. 2010 Jun;51(6):2232-3. doi: 10.1002/hep.23439.
9
Sorafenib for HCC: a pragmatic perspective.索拉非尼用于肝癌治疗：务实的视角
Oncology (Williston Park). 2011 Mar;25(3):300, 302.
10
Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?述评：索拉非尼——肝细胞癌全身治疗漫长探索之旅的终点，还是起点？
Oncologist. 2009 Jan;14(1):92-4. doi: 10.1634/theoncologist.2008-0294. Epub 2009 Jan 14.
引用本文的文献
1
Pharmacoeconomic analysis in Saudi Arabia: an overdue agenda item for action.沙特阿拉伯的药物经济学分析：一项亟待开展的议程项目。
Ann Saudi Med. 2011 Jul-Aug;31(4):335-41. doi: 10.4103/0256-4947.83201.
Zotero 插件